Royalty Report: Drugs, Autoimmune, Disease – Collection: 76567

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Autoimmune
  • Disease
  • Cancer
  • Arthritis
  • Pharmaceuticals
  • cardiac
  • Research
  • Skin care
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 76567

License Grant
We have a worldwide license and collaboration agreement which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases.
Field of Use
This agreement pertains to the drug industry relating to inflammatory and autoimmune diseases.

IPSCIO Record ID: 183244

License Grant
Licensor granted an exclusive, worldwide license to develop and commercialize cerdulatinib in topical formulation for all indications, excluding oncology to German Licensee.
License Property
Cerdulatinib, is an orally available dual kinase inhibitor that inhibits spleen tyrosine kinase, or Syk, and Janus kinases, or JAK, enzymes that regulate important signaling pathways.  Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders.
Field of Use
Licensee intends to develop it for the topical treatment of a range of dermatologic conditions.

This agreement is for the pharmaceutical industry, excluding oncology use.

IPSCIO Record ID: 28062

License Grant
The parties entered into the agreement for the development and commercialization of IMBRUVICATM, a novel, orally active, selective covalent inhibitor of Bruton’s Tyrosine Kinase, and certain compounds structurally related to IMBRUVICATM, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the U.S. and outside the U.S. The collaboration provides Licensee with an exclusive license to exploit the underlying technology outside of the U.S. and co-exclusively with Licensor in the U.S.

IPSCIO Record ID: 329728

License Grant
Each Licensor, one in the United States and one in Japan, grants an exclusive license, with the right to grant sublicenses, under its interest in the Licensed Technology to (a) use the Licensed Technology to identify and develop compounds that inhibit phospholipase, and (b) develop, make, have made, use, import, offer for sale, and sell Compounds and Licensed Products in the Territory. In addition, the Licensor of Japan grants the right to (i) conduct preclinical and clinical studies of Licensed Products outside the Territory solely for the purpose of supporting Applications for Marketing Authorization in the Territory, and (ii) make and have made Compounds and Licensed Products in Japan, which Compounds and Licensed Products are intended for use or sale in the Territory.
License Property
Licensors have intellectual property relating to the discovery, development, and commercialization of compounds that inhibit phospholipase A2.

Compounds means all compounds, and all salts, isomers, solvates, prodrugs, crystalline forms, and habits thereof, that (a) are covered or claimed by the Licensed Patent Rights within the Licensed Technology, (b) were selected by Licensor as a candidate for development as a PLA2 Inhibitor and covered under a Collaboration Agreement, or (c) are PLA2 Inhibitors and were conceived, discovered, synthesized, or acquired by Licensor(s) based upon Project Technology.  Compounds includes, without limitation, the compounds S-5920/LY315920, S-3013/LY33301, RSC-3388, LY433771, LY329722, LY374388, LY311727, LY421079, LY316264, which include infusion injections solutions, oral suspensions and tablets.

PLA2 means any member of the phospholipase A2 family including the known forms of all species and any new forms of the enzyme that share the structural and enzymatic properties of this class.

PLA2 Inhibitor means any substance which decreases the ability of PLA2 to hydrolyze free fatty acids from phospholipids.

Field of Use
Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD.

IPSCIO Record ID: 337709

License Grant
The parties agree to commercialize fostamatinib in all potential indications, including chronic ITP and AIHA, in Canada and Israel.
License Property
Fostamatinib has the brand name of Tavlesse (Tavalisse). It is a tablet, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.

ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.

Field of Use
Field of use is for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments and to reduce the destruction of red blood cells in the AIHA disease.

AIHA means autoimmune hemolytic anemia.  It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.

IPSCIO Record ID: 341530

License Grant
Under the terms of the new arrangement, Belgium Licensee will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe.
License Property
Filgotinib preferential JAK1 inhibitor with a potential best-in-class product profile (Jyseleca). Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor. Jyseleca® is the brand name for filgotinib
Field of Use
Field of Use is for the treatment of IBD (Inflammatory Bowel Disease), CD (Crohns Disease), UC (Ulcerative Colitis) and potentially other inflammatory diseases such as RA (Rheumatiod arthritus).

Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.

Crohn’s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.

Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).

Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.

Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.

IPSCIO Record ID: 212275

License Grant
The Licensor announced that it opted into a cost and profit sharing arrangement for all products developed under a Collaboration and License agreement, including M230. Under the agreement the Licensor will fund a portion of global research and development and U.S. commercialization and manufacturing costs in exchange for a percentage of U.S. profits. M230 is being developed for use in autoimmune diseases.
License Property
M230 (SIF3) is a Selective Immunomodulator of Fc receptors being developed for use in autoimmune diseases. The Licensor develops novel therapeutics for autoimmune indications.
Field of Use
The Licensee is a worldwide specialty bio-therapeutics company targeting a clinical trial of M230 in late 2017.

M230 is a candidate for potential use for patients with autoimmune diseases that are treated with immunoglobulins.'

IPSCIO Record ID: 269086

License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey.  Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)

The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.

Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.

IPSCIO Record ID: 291166

License Grant
Licensor hereby grants Licensee an exclusive (even as to Licensor), royalty-bearing license in the territory, without the right to grant sublicensees, under all Patent Rights and Know-How Controlled by Licensor (other than Patent Rights and Know-How jointly owned by Licensor and one or more of its Third Party collaborators) to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize all JAK-3 Kinase Inhibitors having as their primary mechanism of action JAK-3 Kinase Inhibitory Activity (and products containing any such JAK-3 Kinase Inhibitors) in the Licensee Field during the JAK-3 exclusivity period.

Licenosr hereby grants Licensee an exclusive (even as to Licensee), royalty-bearing license in the  Territory, without the right to grant sublicenses, under all of Licensors rights under all JAK-3 Joint Patent Rights to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize all JAK-3 Kinase Inhibitors having as their primary mechanism of action JAK-3 Kinase Inhibitory Activity (and products containing any such JAK-3 Kinase Inhibitors) in the Licensee Field during the term.

Licensor hereby grants Licensee an exclusive (even as to Licensor), royalty-beariing license in the Territory, with the right to grant sublicenses, (Sublicensing), under the Licensor IP and Licensors rights, title and interests in the Joint IP to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize Licensee Available Compounds (and any Licensee Products containing any such Licensee Available Compounds) in the Licensee Field.

License Property
JAK-3 Kinase Inhibitor means a molecule that has JAK-3 Kinase Inhibitory Activity at an in vitro fifty percent (50%) inhibitory concentration (IC50) of less than or equal to 1 micromolar.

JAK-3 Kinase Inhibitory Activity means, when used to describe a compound, that the compound binds to the protein tyrosine kinase enzyme known as Janus Activating Kinase 3 (JAK-3).

JAK-3 Joint Patent Right means Joint Patent Rights that claim inventions that are reasonably necessary to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize Agreement Compounds.

Licensor Patent Right means all Patent Rights Controlled by Licensor as of the Effective Date or during the term, as are reasonably necessary to Develop, make, have made, use, import or export Agreement Compounds, or to make, have made, use. offer to sell, sell, import, export or otherwise Commercialize Products based thereon; provided, however, that if a Third Party becomes an Affiliate of Licensor pursuant to a Change of Control Transaction as a result of which such Third Party is able to elect a majority of the members of the board of directors of Licensor (or its successor company) or any of its 'controlling Affiliates' (Change of Control Transaction), 'Licensor Patent Rights' not include any Patent Rights that were Controlled by such Third Party (and not by Licensor) prior to the completion of such Change of Control Transaction.  It is understood that Licensor Patent Rights shall not include any intellectual property owned or licensed by Licensor relating to (i) the creation or use of encoding technology for combinatorial libraries, (ii) tag and/or marker compound engineering, encoding or decoding, or (iii) high throughput screening assays.

Licensor Available Compound means
(a)  any Licensor Compound or Collaboration Compound selected by Licensor for Development (Compound Selection) and for which Licensor is fulfilling the diligence obligations required (Compound Selection); and (b)  any Licensor Compound or Collaboration Compound with respect to which Licensor has undertaken Development in the Licensee Field if permitted and for which Licensor is fulfilling the diligence obligations required (Compound Selection).

Patent Rights means any and all (a) patents, (b) pending patent applications, including, without limitation, all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including, without limitation, supplementary protection certificates or the equivalent thereof (d) inventor’s certificates, and (e) all United States and foreign counterparts of any of the foregoing.

Product(s) means Licensor Product(s) or Licensee Product(s), as the case may be.

Licensor Product means a pharmaceutical preparation containing a Licensor Available Compound.  For purposes of clarity, any pharmaceutical preparations containing the same Licensor Available Compound will be deemed to be the same Licensor Product.

Licensee Product means a pharmaceutical preparation containing a Licensee Available Compound.  For purposes of clarity, any pharmaceutical preparations containing the same Licensee Available Compound will be deemed to be the same Licensee Product.  For the avoidance of doubt, a Licensee Product will not be considered to be separate, distinct and different from another Licensee Product solely on the basis of its use for a different indication, method of production or manufacture, method of delivery or dosage level.

Field of Use
JAK3 Inhibitors. A member of the Janus family of tyrosine protein kinases, Janus Kinase-3 (JAK3) plays a critical role in T-cell proliferation via cytokine signaling pathways. Local administration of a selective JAK3 inhibitor represents a potential therapeutic approach for T-cell and cytokine mediated dermatologic and ocular diseases. Included in these are psoriasis, which is characterized by hyper-proliferation of T-cells which present themselves in inflamed skin lesions, and dry eye which is a cytokine-based inflammation of the ocular surface.

Licensor Field means all uses of a Product in non-human animals, and all topical uses of a Product for the treatment or prevention of skin and eye diseases in humans where such Product would be applied directly to the skin or eye and would have its therapeutic effect at or near a target site on the skin or eye.

IPSCIO Record ID: 279346

License Grant
Licensor grants to the Swiss Licensee a sole and exclusive, even as to Licensor, worldwide right and license under the Licensor Patents and Licensor Know-How to make, have made, use, offer for sale, sell and import Licensed Products in the Field.

Licensor grants a nonexclusive, nontransferable. limited right to use the Licensor trademark.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as purine nucleoside phosphorylase inhibitors (PNP Inhibitors), including the compound known as –X-4208.

Compound means the PNP Inhibitor known as –X-4208.

Field of Use
The Field means the prevention or treatment of Autoimmune Indications and Transplantation Indications.

Autoimmune Indications means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens.

Transplantation Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation.

BCX-4208 is for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.